Rocket Pharmaceuticals (RCKT) Research & Development (2014 - 2026)

Rocket Pharmaceuticals has disclosed Research & Development across 13 years of filings, most recently posting $31.5 million for Q1 2026.

• Research & Development for Q1 2026 came in at $31.5 million, down 12.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.5 million (down 15.09% YoY), and the FY2025 annual result was $142.0 million, down 17.07% from the prior year.
• Research & Development came in at $31.5 million for Q1 2026 at Rocket Pharmaceuticals, up from $29.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $51.4 million in Q2 2023 to a low of $29.3 million in Q4 2025.
• The 5-year median for Research & Development is $42.3 million (2024), against an average of $41.0 million.
• Across the five-year window, Research & Development surged 68.59% in 2022 and dropped 21.44% in 2025, its largest moves.
• Rocket Pharmaceuticals' Research & Development stood at $50.0 million in 2022, then retreated by 16.57% to $41.7 million in 2023, then declined by 10.51% to $37.4 million in 2024, then decreased by 21.44% to $29.3 million in 2025, then advanced by 7.18% to $31.5 million in 2026.
• The last three Research & Development figures came in at $31.5 million (Q1 2026), $29.3 million (Q4 2025), and $34.1 million (Q3 2025), per Business Quant data.